Abstract: Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Abstract: Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Abstract: Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Abstract: Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Abstract: Systems and methods for determining the presence and/or amount of analytes in a fluid sample are described.

Abstract: A multi-layered, absorbent perineal pad is disclosed that has a generally ovate cross-section. In disclosed embodiments, the pad has an absorbent outer layer, antimicrobial intermediate layer, and absorbent inner layer. At least two opposing edges of the pad are sealed to one another so that the absorbent inner layer encloses an internal cavity within the pad. The pad may be used to absorb liquids from perineal structures (such as vaginal or anal liquids) or administer agents to perineal structures. Liquids that are absorbed in the pad can be subjected to diagnostic assays.

Abstract: A method is disclosed for absorbing anal leakage, such as fecal material, blood or flatulence. The method includes positioning an intergluteal absorbent pad external to the anal orifice of a subject such that the pad is retained between the buttocks, and any discharge from the anus is absorbed by the absorbent material of the pad. The pad can have a variety of shapes, including major and minor portions that are portions of spheres or ellipsoids, or which are elongated and have cross-sections that are circular or ellipsoid. The smaller minor portion of the pad is positioned against the anal orifice to minimize pressure exerted in this sensitive area, while the larger major portion is retained in the less sensitive intergluteal space. Insertion and retention of the pad adjacent to the anus helps alleviate symptoms of the hemorrhoids, absorbs leakage, and can also be used as a reservoir to administer medication.

Abstract: A diagnostic agent is delivered intravaginally or to the interlabial space by positioning an interlabial device, such as an absorbent pad, between the labia. The pad is retained between the labia to deliver an active agent, or allow a reaction with a diagnostic agent. Alternatively, the pad is applied after the diagnostic agent is administered, to help reduce discomfort to the subject, or loss of the diagnostic agent. The active agent may be carried by the pad itself, or in an intravaginal extension of the pad, or separately in a suppository or other dosage form. In particular examples, the pad has a smaller minor portion superimposed on a larger major portion, and the smaller minor portion is inserted as a leading edge between the labia of the subject to facilitate interlabial insertion. In another example, the pad is placed interlabially after insertion of an agent.

Abstract: A multi-layered, absorbent perineal pad is disclosed that has a generally ovate cross-section. In disclosed embodiments, the pad has an absorbent outer layer, antimicrobial intermediate layer, and absorbent inner layer. At least two opposing edges of the pad are sealed to one another so that the absorbent inner layer encloses an internal cavity within the pad. The pad may be used to absorb liquids from perineal structures (such as vaginal or anal liquids) or administer agents to perineal structures. Liquids that are absorbed in the pad can be subjected to diagnostic assays.

Abstract: A method is disclosed for absorbing anal leakage, such as fecal material, blood or flatulence. The method includes positioning an intergluteal absorbent pad external to the anal orifice of a subject such that the pad is retained between the buttocks, and any discharge from the anus is absorbed by the absorbent material of the pad. The pad can have a variety of shapes, including major and minor portions that are portions of spheres or ellipsoids, or which are elongated and have cross-sections that are circular or ellipsoid. The smaller minor portion of the pad is positioned against the anal orifice to minimize pressure exerted in this sensitive area, while the larger major portion is retained in the less sensitive intergluteal space. Insertion and retention of the pad adjacent to the anus helps alleviate symptoms of the hemorrhoids, absorbs leakage, and can also be used as a reservoir to administer medication.

Abstract: A diagnostic agent is delivered intravaginally or to the interlabial space by positioning an interlabial device, such as an absorbent pad, between the labia. The pad is retained between the labia to deliver an active agent, or allow a reaction with a diagnostic agent. Alternatively, the pad is applied after the diagnostic agent is administered, to help reduce discomfort to the subject, or loss of the diagnostic agent. The active agent may be carried by the pad itself, or in an intravaginal extension of the pad, or separately in a suppository or other dosage form. In particular examples, the pad has a smaller minor portion superimposed on a larger major portion, and the smaller minor portion is inserted as a leading edge between the labia of the subject to facilitate interlabial insertion. In another example, the pad is placed interlabially after insertion of an agent.

Abstract: A device for collecting oral liquids includes a lateral flow chromatography strip having a collection member. The collection member is separated from the remainder of the chromatography strip by a liquid impermeable removable barrier which prevents liquid in the collection member from entering the chromatography strip. Once adequate oral liquid has been collected (as indicated by a sample sufficiency indicator), the barrier is removed to allow oral liquids to flow through the strip. The liquids interact with binding partners in the strip to provide test results, such as an indication that an analyte of interest is present in the liquid. The strip may be contained in a housing with an access opening through which the removable barrier may be manipulated, and windows through which test results may be viewed. This device avoids reflux of reagents from the strip into the mouth of a test subject during use.

Abstract: A device for collecting oral liquids includes a lateral flow chromatography strip having a collection pad for insertion into the mouth. The collection pad is separated from the remainder of the chromatography strip by a liquid impermeable removable barrier which prevents liquid in the collection pad from entering the chromatography strip. Once adequate oral liquid has been collected (as indicated by a sample sufficiency indicator), the device is withdrawn from the mouth and the barrier is removed to allow oral liquids to flow through the strip. The liquids interact with binding partners in the strip to provide test results, such as an indication that an analyte of interest is present in the liquid. The strip may be contained in a housing with an access opening through which the removable barrier may be manipulated, and windows through which test results may be viewed. This device avoids reflux of reagents from the strip into the mouth of a test subject during use.

Abstract: A method is provided for enhancing hematopoiesis. The method includes transplanting at least a therapeutically effective portion of an isolated vascular tissue into a subject, wherein the vascular tissue enhances hematopoiesis. A method is also provided for detecting an agent that affects hematopoiesis. The method includes transplanting a portion of an isolated vascular tissue into a subject, wherein the portion of the isolated vascular tissue is sufficient to enhance hematopoiesis. The vascular tissue is treated with an agent, and hematopoiesis is detected in the subject. Hematopoiesis in the subject is compared with hematopoietic in a control. A change in hematopoiesis in the subject as compared to the control indicatives that the agent affects hematopoiesis. A method is provided for isolating a hematopoiesis growth factor using the method of the invention. In addition, a method is provided for isolating a hematopoietic stem cell using the method of the invention.

Abstract: A drug or diagnostic agent) is delivered intravaginally or to the interlabial space by positioning an interlabial device, such as an absorbent pad, between the labia. The pad is retained between the labia to deliver an active agent, or allow a reaction with a diagnostic agent. Alternatively, the pad is applied after medication is administered, to help reduce discomfort to the subject, or loss of medication. The active agent may be carried by the pad itself, or in an intravaginal extension of the pad, or separately in a suppository or other dosage form. In particular examples, the pad has a smaller minor portion superimposed on a larger major portion, and the smaller minor portion is inserted as a leading edge between the labia of the subject to facilitate interlabial insertion. In another example, the pad is placed interlabially after insertion of an agent into the vagina.

Abstract: A method is disclosed for administering an agent (for example delivering a drug or diagnostic agent) intravaginally or to the interlabial space by positioning an interlabial device, such as an absorbent pad, between the labia. The pad is retained between the labia for a sufficient period of time to deliver an active agent, or allow a reaction with a diagnostic agent. Alternatively, the pad is applied after medication is administered, for example intravaginally or labially or perilabially, to help reduce discomfort to the subject, or loss of medication. The active agent may be carried by the pad itself, or in an intravaginal extension of the pad, or separately in a suppository or other dosage form. In particular examples, the pad has a smaller minor portion superimposed on a larger major portion, and the smaller minor portion is inserted as a leading edge between the labia of the subject to facilitate interlabial insertion.

Abstract: A device for collecting oral liquids includes a lateral flow chromatography strip having a collection pad for insertion into the mouth. The collection pad is separated from the remainder of the chromatography strip by a liquid impermeable removable barrier which prevents liquid in the collection pad from entering the chromatography strip. Once adequate oral liquid has been collected (as indicated by a sample sufficiency indicator), the device is withdrawn from the mouth and the barrier is removed to allow oral liquids to flow through the strip. The liquids interact with binding partners in the strip to provide test results, such as an indication that an analyte of interest is present in the liquid. The strip may be contained in a housing with an access opening through which the removable barrier may be manipulated, and windows through which test results may be viewed. This device avoids reflux of reagents from the strip into the mouth of a test subject during use.

Abstract: There is provided a method and apparatus for collecting vaginal fluid and exfoliated vaginal cells for medical diagnostic purposes. An absorbent media is placed interlabially or intravaginally. Fluid is collected within the absorbent media. The absorbent media is removed, and the fluid is extracted therefrom. For intravaginal collection, the absorbent media may be placed in a housing having fluid receiving apertures therein. Medical diagnostic testing is performed on the extracted fluid.

Abstract: The present invention provides a non-human genetically immunodeficient mammal the peripheral blood of which contains a non-lethal percent of T-cells of human origin which is at least 20% as well as a non-human genetically immunodeficient mammal having a lethal percent of T-cells of human origin in the peripheral blood which is at least 60%. Also provided is a method of screening a substance for anti-HIV activity comprising obtaining a non-human genetically immunodeficient mammal having a lethal percent of human T-cells in the peripheral blood which is at least 60%; infecting the mammal with an amount of HIV sufficient to rescue the mammal from death from the effects of the lethal percent of human T-cells; administering the substance to the mammal; and determining if the substance kills the mammal by inhibiting the rescue of the mammal by HIV, the death of the mammal indicating a substance having anti-HIV activity.

Abstract: There is provided a method and apparatus for collecting vaginal fluid and exfoliated vaginal cells for medical diagnostic purposes. An absorbent media is placed interlabially or intravaginally. Fluid is collected within the absorbent media. The absorbent media is removed, and the fluid is extracted therefrom. For intravaginal collection, the absorbent media may be placed in a housing having fluid receiving apertures therein. Medical diagnostic testing is performed on the extracted fluid.